Glenmark Life Sciences Q3 FY22 Investor Presentation

Glenmark Life Sciences Q3 FY22 earnings presentation covering financial performance with 4.5% YoY revenue growth and strong CDMO business momentum at 45.1% growth. EBITDA margins held steady at 28.6% while the company demonstrated operational resilience despite headwinds in generic API business from COVID-19 base effects.